Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Quintiles to Offer More Risk-Sharing Business Models: Dr Winstanly
January 4, 2010
- 78.1% of Consumers against Exclusion of Poultices from Insurance Coverage: Survey
January 4, 2010
- Eisai Confident of Overcoming Aricept Patent Expiration: Mr Naito
January 4, 2010
- Keidanren Lists Healthcare, Drugs as Major Growth Fields
January 4, 2010
- Multaq Approved by EC for AF: sanofi-aventis
January 4, 2010
- NOF Licenses Polymer-Micelle Carrier Technology from NanoCarrier
January 4, 2010
- H1N1 Vaccine Arepanrix Prequalified by WHO: GSK
January 4, 2010
- Kyowa Hakko Bio to Transfer Domestic Livestock, Aquaculture Business to ASKA
January 4, 2010
- Shionogi: Locusta for Hypercholesterolemia
January 4, 2010
- Pharmacies Don't Need Wholesalers’Information Services: Mr Fukai of Nihon Chouzai
January 4, 2010
- Mail-Order Drug Market Down 22.7% in 2009
January 4, 2010
- Teva-Kowa Aims at 10% Share in Generics Market
January 4, 2010
- Bendamustine's Efficacy Confirmed for Low-Grade NHL: SymBio
January 4, 2010
- JCR Allies with GSK for Biosimilars
January 4, 2010
- GSK Considers Disclosing All Payments to Med Institutions
January 4, 2010
- Ms Bresch Calls For Generics Promotion Measures Easier for General Consumers to Understand
January 4, 2010
- TAK-085 Enters PIII for Hypertriglyceridemia in Japan: Takeda
January 4, 2010
- Chuikyo OKs Measures Proposed by Korosho to Promote Use of Generics
January 4, 2010
- Novo Nordisk Starts PI for Oral Insulin Analogue in Germany
January 4, 2010
- Premium Decided at 80% of Korosho Proposal, Long-Listed Products to See 2.2% Price Cut
January 4, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…